BL2 PATIENT PREFERENCES FOR BIOLOGIC AGENTS IN RHEUMATOID ARTHRITIS: A DISCRETE CHOICE EXPERIMENT
نویسندگان
چکیده
منابع مشابه
Eliciting Preferences for Health Insurance in Iran Using Discrete Choice Experiment Analysis
Background The preferences of Iranians concerning the attributes of health insurance benefit packages are not well studied. This study aimed to elicit health insurance preferences among insured people in Iran during 2016. Methods A mixed method...
متن کاملDoctors’ preferences in de-escalating DMARDs in rheumatoid arthritis: a discrete choice experiment
BACKGROUND Current guidelines suggest reduction of DMARDs can be considered in RA patients in remission. Objectives were (1) to estimate the relative importance of patient characteristics rheumatologists consider in their decision to de-escalate (2) to assess whether heterogeneity exists among rheumatologists with respect to de-escalation and (3) to identify the preferred de-escalation strategy...
متن کاملPatient preferences for asthma therapy: a discrete choice experiment.
AIM This study was designed to capture patient preferences for different aspects of asthma treatment from people with asthma in the UK, the Netherlands and Spain. METHODS Asthma patients from the UK (n=124), the Netherlands (n=269) and Spain (n=86) participated in the survey. Patients' preferences and willingness to pay for a particular number of preventer inhalers, in relation to days per we...
متن کاملPatient preferences for HIV/AIDS therapy - a discrete choice experiment
OBJECTIVES An increasing emphasis on patient-centred health care and shared decision making requires an intensive consideration of patient preferences. In the present study, patient preferences regarding treatment of HIV/AIDS were explored using direct assessment and discrete choice experiment (DCE). METHODS Based on literature research about preferences of HIV/AIDS patients we conducted a qu...
متن کاملExamining patient preferences in the treatment of rheumatoid arthritis using a discrete-choice approach
BACKGROUND Biological disease-modifying antirheumatic drugs (bDMARDs) used in second-line treatment of rheumatoid arthritis (RA) are administered parenterally. However, so-called targeted synthetic DMARDs (tsDMARDs) - developed more recently - offer alternative (ie, oral) administration forms in second-line treatment. Since bDMARDs and tsDMARDs can be regarded as equal in terms of efficacy, the...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Value in Health
سال: 2010
ISSN: 1098-3015
DOI: 10.1016/s1098-3015(11)71863-0